Please register your interest by emailing enquiries@pacificchannel.com to receive an executive summary of current investment opportunities.

Why invest in Life Sciences?

The global life sciences and biotechnology industry is one of the greatest sources of innovation available today.

Life science research has resulted in scores of breakthrough therapies and new methods for the early detection of disease.

Life science research has also improved agricultural yields to meet increasing demands for food, reduced pesticide use and new methods of environmental remediation.

Mega trends such as the worldwide increase in populations over the age of 60, and forecasted substantial increases in the populations of underdeveloped countries will drive the need for an increasing range of new, cost-effective health care and agricultural products for decades to come.

Industrial and environmental biotechnologies are developing new processes to replace fossil fuels. Industrial biotechnology applications have led to cleaner processes that produce less waste and use less energy and water.

It is clear that the endeavours and applications of life sciences are broad and increasingly global in scope. The Life Sciences markets today represent a unique opportunity to invest in companies at varying stages of development at prices that are depressed relative to historical levels.

For more information visit the Biotechnology Industry Organizations’ sites: http://www.NZBIO.org.nz, http://www.bio.org/

Why invest in New Zealand Life Science companies?

New Zealand has a history of excellence in life sciences research in food and agriculture as a result of its significant government investment, focus on biology based industries and researchers trained in leading institutions around the globe.

Pacific Channel believes that New Zealand companies offer an excellent opportunity to yield substantial returns for investors. New Zealand has world leading science yet, there is a lack of available investment funding. Technology and company valuations are relatively low from a global perspective.

A significant advantage is enjoyed by New Zealand through low research costs and time and cost efficient early-stage clinical studies.

New Zealand has a high per capita population of scientists and industrial engineers. This has resulted in an integrated workforce capable of the manufacture of products resulting from life sciences research.

New Zealand has a long history of investment into research and development in academic laboratories and in the country’s government owned Crown Research Institutes.

Development and manufacturing costs are expected to be significantly lower than in most developed countries, with the Government establishing supportive policies and regulations to promote industry
growth.

New Zealand is ranked number 2 out of 134 countries surveyed by Forbes to identify "Best Countries for doing Business".

New Zealand is ranked as one of the world's least corrupt countries.